Annovis Bio received NYSE delisting notice

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On October 29, 2026, Annovis Bio, Inc. (the "Company") received notice (the "Notice") from the New York Stock Exchange (the "NYSE") that it is no longer in compliance with the NYSE continued listing standards set forth in Section 802.01B of the NYSE's Listed Company Manual due to the fact that the Company's average market capitalization over a consecutive 30 trading-day period was less than $50 million and, at the same time, its stockholders' equity was less than $50 million. The Notice further states that as of October 28, 2026, the Company's 30 trading-day average market capitalization was approximately $48.4 million and its last reported stockholders' deficit as of June 30, 2026 was approximately $(4.3) million.

In accordance with NYSE listing requirements, the Company has notified the NYSE that it will submit a plan within 45 days of the Notice advising the NYSE of definitive action it has taken, or is taking, to bring it into conformity with Section 802.01B within 9 months of receipt of the Notice. The NYSE will review the Company's plan and, within 45 days make a determination as to whether the Company has made a reasonable demonstration of its ability to come into conformity with Section 802.01B within 9 months. If the Company's plan is not submitted on a timely basis or is not accepted, the NYSE will initiate delisting proceedings. If the NYSE accepts the Company's plan, the Company's common stock will continue to be listed and traded on the NYSE during the cure period, subject to the Company's compliance with the plan and other continued listing standards. The NYSE will review the Company on a semi-annual basis to confirm compliance with the plan. If the Company fails to comply with the plan or does not meet continued listing standards at the end of the 9-month cure period, it will be subject to the prompt initiation of NYSE suspension and delistin

Item 7.01 Regulation FD Disclosure

The Company issued a press release announcing the receipt of the Notice. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.

The information in this report (including Exhibit 99.1) shall not be deemed to be "filed" for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Cautionary Note Regarding Forward-Looking Statements

This report and the furnished press release contains, and oral statements made from time to time by our representatives may contain, "forward-looking statements." Forward-looking statements include statements identified by words such as "could," "may," "might," "will," "intends," "plans," "seeks," "believes," "estimates," "expects," "continues," "projects" and similar references to future periods, or by the inclusion of forecasts or projections.

Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, the Company's ability to develop a plan to regain compliance with the continued listing criteria of the NYSE; the NYSE's acceptance of such plan; th

ITEM 9.01 Financial Statements and Exhibits

Exhibit Number

Description

99.1

Press Release dated October 30, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANNOVIS BIO, INC.

Date: October 30, 2026

By:

/s/ Maria Maccecchini

Name: Maria Maccecchini

Title: Chief Executive Officer

ANNOVIS BIO, INC. RECEIVES CONTINUED LISTING STANDARD NOTICE FROM THE NYSE

MALVERN, PA - October 30, 2026 - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that on October 29, 2026, it received notice (the "Notice") from the New York Stock Exchange (NYSE) that it is no longer in compliance with the NYSE continued listing standards set forth in Section 802.01B of the NYSE's Listed Company Manual due to the fact that the Company's average market capitalization over a consecutive 30 trading-day period was less than $50 million while its stockholders' equity was less than $50 million.

The Notice does not affect the Company's business operations or its reporting obligations with the Securities and Exchange Commission, and it does not conflict with or cause an event of default under any of the Company's material debt or other agreements.

As set forth in the Notice, as of October 28, 2026, the 30 trading-day average market capitalization of the Company was approximately $48.4 million and the Company's last reported stockholders' deficit as of June 30, 2026 was approximately $(4.3) million.

The Company has notified the NYSE that it will submit a plan within 45 days of the Notice advising the